English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Objective  To assess the frequency of venous thromboembolism ( VTE ) events in the Rituximab in Antineutrophil Cytoplasmic Antibody ( ANCA )–Associated Vasculitis ( RAVE ) trial and identify novel potential risk factors.    Methods   VTE  events in 197 patients enrolled in the  RAVE  trial were analyzed. Baseline demographic and clinical characteristics were recorded, and univariate and multivariate analyses were performed to identify factors associated with  VTE  in  ANCA ‐associated vasculitis ( AAV ).    Results   VTE  occurred in 16 patients (8.1%) with an overall average time to event of 1.5 months (range 1.0–2.75). In univariate analyses with calculation of hazard ratios ( HR s) and 95% confidence intervals (95%  CI s), heart involvement ( HR  17.408 [95%  CI  2.247–134.842];  P  = 0.006), positive proteinase 3 ( PR 3)– ANCA  ( HR  7.731 [95%  CI  1.021–58.545];  P  = 0.048), pulmonary hemorrhage ( HR  3.889 [95%  CI  1.448–10.448];  P  = 0.008), and the presence of red blood cell casts ( HR  15.617 [95%  CI  3.491–69.854];  P  < 0.001) were associated with the onset of  VTE . In multivariate models adjusted for age and sex, the significant associations between  VTE  events and heart involvement ( HR  21.836 [95%  CI  2.566–185.805];  P  = 0.005),  PR 3‐ ANCA  ( HR  9.12 [95%  CI  1.158–71.839];  P  = 0.036), pulmonary hemorrhage ( HR  3.91 [95%  CI  1.453–10.522];  P  = 0.007), and urinary red blood cell casts ( HR  16.455 [95%  CI  3.607–75.075];  P  < 0.001) remained.    Conclusion  Patients diagnosed as having  AAV  with pulmonary hemorrhage, positive  PR 3‐ ANCA , heart involvement, and the presence of red blood cell casts are at an increased risk to develop  VTE . Further studies are needed to confirm and expand these findings and to explore the mechanisms of hypercoagulability in these patients with the aim of informing potential targets for therapeutic intervention.

arthritis and rheumatology

Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis